Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

  • STATUS
    Not Recruiting
  • days left to enroll
    75
  • participants needed
    267
  • sponsor
    Novartis Pharmaceuticals
Updated on 25 July 2021
Investigator
Novartis Pharmaceuticals
Primary Contact
Novartis Investigative Site (4.5 mi away) Contact
+17 other location
measurable disease
pd-l1
pdr001
sclc
mbg453

Summary

The purpose of this first-in-human study of MBG453 is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v. as a single agent or in combination with PDR001 or decitabine in adult patients with advanced solid tumors

Details
Condition Advanced Malignancies
Treatment Decitabine, PDR001, MBG453
Clinical Study IdentifierNCT02608268
SponsorNovartis Pharmaceuticals
Last Modified on25 July 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note